Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 89

1.

Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.

Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P.

Am J Transplant. 2007 Nov;7(11):2496-503. Epub 2007 Oct 1.

2.

Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients.

Wang CX, Meng FH, Chen LZ, Ren B, Li SX, Fei JG, Qiu J, Deng SX, Li J, Chen SY.

Transplant Proc. 2007 Jun;39(5):1392-5.

PMID:
17580146
3.

Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients.

Heller T, van Gelder T, Budde K, de Fijter JW, Kuypers D, Arns W, Schmidt J, Rostaing L, Powis SH, Claesson K, Macphee IA, Pohanka E, Engelmayer J, Brandhorst G, Oellerich M, Armstrong VW.

Am J Transplant. 2007 Jul;7(7):1822-31. Epub 2007 May 26.

4.

Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.

Bilbao I, Castells L, Rojas L, Cancino J, Dopazo C, Castro E, Pou L, Andino R, Margarit C.

Int Immunopharmacol. 2006 Dec 20;6(13-14):1977-83. Epub 2006 Oct 24.

PMID:
17161351
5.

Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension.

Orlando G, Baiocchi L, Cardillo A, Iaria G, De Liguori Carino N, De Luca L, Ielpo B, Tariciotti L, Angelico M, Tisone G.

Liver Transpl. 2007 Jan;13(1):46-54. Erratum in: Liver Transpl. 2007 May;13(5):778. De Liguori, Nicola [corrected to De Liguori Carino, Nicola].

6.

Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.

Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y.

Transplantation. 2006 Oct 27;82(8):1074-84.

PMID:
17060857
7.

Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.

Weber LT, Hoecker B, Armstrong VW, Oellerich M, Tönshoff B.

Ther Drug Monit. 2006 Oct;28(5):623-31.

PMID:
17038876
8.

Clinical pharmacokinetics of mycophenolate mofetil in Japanese renal transplant recipients: A retrospective cohort study in a single center.

Sugioka N, Sasaki T, Kokuhu T, Ito Y, Shibata N, Okamoto M, Yoshimura N, Takada K.

Biol Pharm Bull. 2006 Oct;29(10):2099-105.

9.
10.

Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients.

Satoh S, Tada H, Murakami M, Tsuchiya N, Li Z, Numakura K, Saito M, Inoue T, Miura M, Hayase Y, Suzuki T, Habuchi T.

Transplantation. 2006 Aug 27;82(4):486-93.

PMID:
16926592
11.

The weight of pharmacokinetic parameters for mycophenolic acid in prediction of rejection outcome: the receiver operating characteristic curve analysis.

Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Ostrowska J, Gralak B, Majchrzak J.

Transplant Proc. 2006 Jan-Feb;38(1):86-9.

PMID:
16504671
12.

Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil.

Brunet M, Cirera I, Martorell J, Vidal E, Millán O, Jiménez O, Rojo I, Londoño MC, Rimola A.

Transplantation. 2006 Feb 27;81(4):541-6.

PMID:
16495801
13.

Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.

Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.

J Clin Pharm Ther. 2006 Feb;31(1):27-34.

PMID:
16476117
14.

Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.

Naito T, Shinno K, Maeda T, Kagawa Y, Hashimoto H, Otsuka A, Takayama T, Ushiyama T, Suzuki K, Ozono S.

Biol Pharm Bull. 2006 Feb;29(2):275-80.

15.

Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.

Borrows R, Chusney G, Loucaidou M, James A, Lee J, Tromp JV, Owen J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D.

Am J Transplant. 2006 Jan;6(1):121-8.

16.

Mycophenolic acid plasma trough level: correlation with clinical outcome.

Barbari A, Stephan A, Masri MA, Kamel G, Karam A, Mourad N, Kilani H, El Ghoul B.

Exp Clin Transplant. 2005 Dec;3(2):355-60.

17.

Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency.

González-Roncero FM, Gentil MA, Brunet M, Algarra G, Pereira P, Cabello V, Peralvo M.

Transplant Proc. 2005 Nov;37(9):3749-51.

PMID:
16386526
18.
19.

Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience.

Zakliczyński M, Szewczyk M, Zakliczyńska H, Zembala M.

Ann Transplant. 2005;10(2):38-45.

PMID:
16218032
20.

Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients.

Lu XY, Huang HF, Sheng-Tu JZ, Liu J.

J Zhejiang Univ Sci B. 2005 Sep;6(9):885-91.

Supplemental Content

Support Center